Enzon Pharmaceuticals Inc
ENZN
Market Cap$5.37M
Close$
Share Statistics
| Market cap | $5.37 Million |
|---|---|
| Enterprise Value | $-41,183,863.00 |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-0.0 |
| Beta | 0.0 |
| Outstanding Shares | 74,214,603 |
| Avg 30 Day Volume | 16,719 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -22.3 |
|---|---|
| PEG | 36.23 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -1583.99 |
| Enterprise Value to EBIT | 39.64 |
| Enterprise Value to Net Income | 170 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
ESG Score
No data
About Enzon Pharmaceuticals Inc
CEO: Andrew Rackear Enzon Pharmaceuticals, Inc is a pharmaceutical company engaged in developing therapeutics to patients whose needs are unmet. Its headquarters is now in Piscataway, New Jersey. The company is a publicly traded company on NASDAQ under the ...